Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
06/2012
06/28/2012US20120164151 Methods for Treatment of Muscular Dystrophy
06/28/2012US20120164150 Monoclonal Antibodies Against Activated Protein C
06/28/2012US20120164149 Use of inhibitors of leukotriene b4 receptor blt2 for treating asthma
06/28/2012US20120164148 Compositions Containing JARID1B Inhibitors and Methods for Treating Cancer
06/28/2012US20120164147 Mammalian genes; related reagents and methods
06/28/2012US20120164146 Isolated monophosphorylated peptide derived from human alpha-enolase useful for diagnosis and treatment of pancreatic adenocarcinoma, antibodies directed against the said monophosphorylated peptide, and uses thereof
06/28/2012US20120164145 H. pylori lipopolysaccharide outer core epitope
06/28/2012US20120164144 Novel anti-il13 antibodies and uses thereof
06/28/2012US20120164143 Human monoclonal antibodies against interleukin 8 (il-8)
06/28/2012US20120164142 Compositions comprising natriuretic peptides and methods of use thereof
06/28/2012US20120164141 Methods and compositions for inducing apoptosis
06/28/2012US20120164140 Hemojuvelin fusion proteins and uses thereof
06/28/2012US20120164139 Dopamine 3 receptor agonist and antagonist treatment of gastrointestinal motility disorders
06/28/2012US20120164138 Use of anti-cd1 antibodies for the modulation of immune responses
06/28/2012US20120164137 Anti-folate receptor alpha antibody glycoforms
06/28/2012US20120164136 Compositions and Methods for Treatment of Cancer by Disrupting the LH/LHR Signaling Pathway
06/28/2012US20120164135 Method for preparing comprehensive anti-surface antibody using microorganism immobilized as antigen with protein crosslinking and immobilization reagent
06/28/2012US20120164134 Sugar-free chewable supplement
06/28/2012US20120164133 Methods of identifying an organism
06/28/2012US20120164104 Composition and Methods of Treating Viral Infections and Viral Induced Tumors
06/28/2012US20120164103 Compounds and Methods for the Treatment or Prevention of Flavivirus Infections
06/28/2012US20120164102 Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof
06/28/2012US20120164099 Use of human prostate cell lines in cancer treatment
06/28/2012US20120164076 Methods of treatment using thymus-derived compositions
06/28/2012US20120164074 Methods of diagnosing, preventing and treating cancer metastasis
06/28/2012US20120164071 Compositions and Methods Comprising Phosphatidylethanolamine-Binding Peptide Derivatives
06/28/2012US20120164068 Immuno-conjugates and methods for producing them
06/28/2012US20120164067 Methods of preventing or treating pain using anti-ngf antibodies that selectively inhibit the association of ngf with trka, without affecting the association of ngf with p75
06/28/2012US20120164066 Antigen-binding proteins comprising recombinant protein scaffolds
06/28/2012CA2824279A1 Modified antibody with improved half-life
06/28/2012CA2824278A1 Modulating agonistic tnfr antibodies
06/28/2012CA2822716A1 Recombinant mycobacterium as a vaccine
06/28/2012CA2822715A1 Determination of the efficacy of an anti-mycobacterial vaccination
06/28/2012CA2822684A1 Oprf/i agents and their use in hospitalized and other patients
06/28/2012CA2822639A1 Methods for treating systemic lupus erythematosus using hiv protease inhibitors
06/28/2012CA2822610A1 Anti-p-selectin antibodies and methods of their use and identification
06/28/2012CA2822443A1 Modified influenza hemagglutinin proteins and uses thereof
06/28/2012CA2822366A1 Active protease-resistant antibody fc mutants
06/28/2012CA2822359A1 Enhanced immune response in bovine species
06/28/2012CA2822288A1 Anti-c5/c5a/c5adesr antibodies and fragments
06/28/2012CA2822266A1 Vaccines based on peptides of the complement protein c5a
06/28/2012CA2821574A1 Virus like particle production in plants
06/28/2012CA2821422A1 Vaccines with live bacterial isolates for systemic administration
06/28/2012CA2820953A1 Anti-pcsk9 antibodies and methods of use
06/28/2012CA2819269A1 Anti-mesothelin antibodies and immunoconjugates
06/28/2012CA2819120A1 Stable immunogenic compositions of staphylococcus aureus antigens
06/27/2012EP2468776A2 Anti-Robo4 antibodies and uses therefor
06/27/2012EP2468775A1 Anti-ICAM1 antibodies for inducing apoptosis
06/27/2012EP2468771A1 Pharmaceutical composition containing anti-hb-egf antibody as active ingredient
06/27/2012EP2468769A1 Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof
06/27/2012EP2468763A2 HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
06/27/2012EP2468302A1 New indications for anti-IL-1beta therapy
06/27/2012EP2468301A1 New indications for anti-IL-1-beta therapy
06/27/2012EP2468300A1 Vaccine composition containing synthetic adjuvant
06/27/2012EP2468299A2 Compositions for inducing immune responses
06/27/2012EP2468298A1 Methods of optimizing vaccine production
06/27/2012EP2468297A2 Methods for identifying AGG motif binding agents
06/27/2012EP2468296A2 Yeast-based vaccine for inducing an immune response
06/27/2012EP2468295A1 Vaccines based on peptides of the complement protein C5a
06/27/2012EP2467492A2 Methods and compositions for the treatment of proliferative and pathogenic diseases
06/27/2012EP2467484A2 Porcine torque teno virus vaccines and diagnosis
06/27/2012EP2467404A1 Anti p2x7 receptor antibodies and fragments thereof
06/27/2012EP2467165A2 Targeted immunoconjugates
06/27/2012EP2467164A2 Antibodies against the ectodomain of erbb3 and uses thereof
06/27/2012EP2467163A2 Mimotopes of hiv and uses thereof
06/27/2012EP2467162A1 Therapeutic methods and compositions
06/27/2012EP2467161A1 Methods for diagnosing diabetes and determining effectiveness of treatments
06/27/2012EP2467160A2 Materials and methods for the development of an antigen-specific immune non-responsiveness state
06/27/2012EP2467159A1 Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
06/27/2012EP2467158A2 Recombinant avian paramyxovirus vaccine and method for making and using thereof
06/27/2012EP2467157A1 Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
06/27/2012EP2467156A1 Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents
06/27/2012EP2467155A1 Multiepitope vaccine for her2/neu-associated cancers
06/27/2012EP2467153A1 Use of mimotopes of alpha-synuclein epitopes for treating lewy body diseases
06/27/2012EP2467152A1 Use of nkg2d inhibitors for treating cardiovascular and metabolic diseases, such as type 2 diabetes
06/27/2012EP2201103B1 Treatment of tumours using t lymphocyte preparations
06/27/2012EP2174956B1 Compositions for anti-fibrinolitic treatment
06/27/2012EP2068922B1 Anti-il-13r alpha 1 antibodies and their uses thereof
06/27/2012EP2061505B1 Composition for eliciting a specific ctl response, comprising a lympho-ablative compound and a molecule that contains antigenic sequences and targets professional antigen presenting cells
06/27/2012EP1993605B1 Dry powder compositions and systems for poultry vaccination
06/27/2012EP1976987B1 Cancer-associated Scratch variant
06/27/2012EP1973566B1 An adjuvant system comprising virosomes and liposomes
06/27/2012EP1949902B1 USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
06/27/2012EP1735027B1 Stabilized biodegradable neurotoxin implants
06/27/2012EP1716173B8 Carcinoembryonic antigen fusion protein and uses thereof
06/27/2012EP1708749B1 Mucosal vaccine adjuvants containing bacterial flegellins as an active component
06/27/2012EP1581171B1 Antibodies against gpr64 and uses thereof
06/27/2012EP1034277B1 Extracellular matrix-binding proteins from Staphylococcus aureus
06/27/2012CN1914314B Method of producing virus
06/27/2012CN1878566B Multi-antigen vectors of melanoma
06/27/2012CN1863552B Tyrosinase mutant and methods of use thereof
06/27/2012CN1816524B Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
06/27/2012CN102517331A 2 type subunit vaccine for porcine circovirus as well as preparation method and application thereof
06/27/2012CN102517252A Biological materials and uses thereof
06/27/2012CN102517232A Resistance marker-free porcine actinobacillus pleuropneumoniae double-gene defective strain, construction method and application thereof
06/27/2012CN102516394A CMG 2mutant and Fc fusion protein, its encoding gene and its application
06/27/2012CN102516392A Cancer-targeted super antigen fusion protein, and preparation method and application thereof
06/27/2012CN102516383A Novel mite allergen
06/27/2012CN102516373A Pneumococcal surface protein A without human homology, purification method and application thereof
06/27/2012CN102516363A CTL (Cytotoxic T Lymphocytes) epitope peptide from PL2L60 source and application thereof
1 ... 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 ... 1823